Allele Frequencies and Genotype Distribution of Three Metformin Transporter Polymorphisms in Mexican Population and Their Application in Pharmacogenomics of Type 2 Diabetes

Overview

Journal Front Pharmacol

Date 2024 Nov 18

PMID 39555090

Authors

Oscar I Chavez-Arreola

Brissia Lazalde

Marisol Lopez-Lopez

Alberto Ortega-Vazquez

Quitzia L Torres-Salazar

Affiliations

Soon will be listed here.

Abstract

Background: Metformin is the first-line antidiabetic therapy for type 2 diabetes in Mexico, despite recent recommendations highlighting alternatives like GLP-1 receptor agonists for individuals with obesity. Metformin elimination is reliant on liver and kidney function, and variants in transport proteins such as Multidrug and Toxin Extrusion Protein 1 (MATE1), MATE2, and Organic Cation Transporter 2 (OCT2) can influence its pharmacokinetics. Understanding these variants' frequencies in the Mexican population is crucial for tailoring personalized treatment strategies.

Objective: This study aimed to determine the genotypic and allelic frequencies of key variants in metformin transporters within a Mexican population, addressing the interindividual variability in drug response.

Methodology: Genetic analysis was conducted on 101 healthy, unrelated Mexican subjects who were genotyped for the MATE1, MATE2, and OCT2 variants using allele-specific real-time PCR assays.

Results: The allele frequencies were 0.07 for OCT2, 0.23 for MATE1, and 0.67 for MATE2. The g.-66T→C variant was found only in wild-type and heterozygous forms. Comparative analysis indicated significant differences in allele frequencies between this Mexican population and other ethnic groups, highlighting potential implications for metformin efficacy and safety.

Conclusion: This study provides crucial insights into the genetic variability of metformin transporter genes in a Mexican population, offering a foundation for personalized therapeutic approaches in type 2 diabetes management.

References

Christensen M, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H . The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics. 2011; 21(12):837-50. DOI: 10.1097/FPC.0b013e32834c0010. View

Sato T, Masuda S, Yonezawa A, Tanihara Y, Katsura T, Inui K . Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1. Biochem Pharmacol. 2008; 76(7):894-903. DOI: 10.1016/j.bcp.2008.07.005. View

Leabman M, Huang C, Kawamoto M, Johns S, Stryke D, Ferrin T . Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics. 2002; 12(5):395-405. DOI: 10.1097/00008571-200207000-00007. View

Dudley A, Bleasby K, Brown C . The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers. Br J Pharmacol. 2000; 131(1):71-9. PMC: 1572285. DOI: 10.1038/sj.bjp.0703518. View

Stocker S, Morrissey K, Yee S, Castro R, Xu L, Dahlin A . The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther. 2012; 93(2):186-94. PMC: 3671611. DOI: 10.1038/clpt.2012.210. View

Li J, Perry J, Jablonski K, Srinivasan S, Chen L, Todd J . Identification of Genetic Variation Influencing Metformin Response in a Multiancestry Genome-Wide Association Study in the Diabetes Prevention Program (DPP). Diabetes. 2022; 72(8):1161-1172. PMC: 10382652. DOI: 10.2337/db22-0702. View

Wang Z, Yin O, Tomlinson B, Chow M . OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics. 2008; 18(7):637-45. DOI: 10.1097/FPC.0b013e328302cd41. View

Konig J, Zolk O, Singer K, Hoffmann C, Fromm M . Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations. Br J Pharmacol. 2010; 163(3):546-55. PMC: 3101617. DOI: 10.1111/j.1476-5381.2010.01052.x. View

Raj G, Mathaiyan J, Wyawahare M, Srinivasa Rao K, Priyadarshini R . Genetic polymorphisms of multidrug and toxin extrusion proteins (MATE1 and MATE2) in South Indian population. Bioimpacts. 2017; 7(1):25-30. PMC: 5439386. DOI: 10.15171/bi.2017.04. View

10.

Alexander G, Sehgal N, Moloney R, Stafford R . National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med. 2008; 168(19):2088-94. PMC: 2868588. DOI: 10.1001/archinte.168.19.2088. View

11.

Choi J, Yee S, Ramirez A, Morrissey K, Jang G, Joski P . A common 5'-UTR variant in MATE2-K is associated with poor response to metformin. Clin Pharmacol Ther. 2011; 90(5):674-84. PMC: 3329222. DOI: 10.1038/clpt.2011.165. View

12.

Song I, Shin H, Shim E, Jung I, Kim W, Shon J . Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther. 2008; 84(5):559-62. DOI: 10.1038/clpt.2008.61. View

13.

Omote H, Hiasa M, Matsumoto T, Otsuka M, Moriyama Y . The MATE proteins as fundamental transporters of metabolic and xenobiotic organic cations. Trends Pharmacol Sci. 2006; 27(11):587-93. DOI: 10.1016/j.tips.2006.09.001. View

14.

. Introduction and Methodology: Standards of Care in Diabetes-2024. Diabetes Care. 2023; 47(Supplement_1):S1-S4. PMC: 10725799. DOI: 10.2337/dc24-SINT. View

15.

Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T . Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005; 20(5):379-86. DOI: 10.2133/dmpk.20.379. View

16.

Zu Schwabedissen H, Verstuyft C, Kroemer H, Becquemont L, Kim R . Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010; 298(4):F997-F1005. DOI: 10.1152/ajprenal.00431.2009. View

17.

Chen Y, Li S, Brown C, Cheatham S, Castro R, Leabman M . Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics. 2009; 19(7):497-504. PMC: 3104496. DOI: 10.1097/FPC.0b013e32832cc7e9. View

18.

Sole X, Guino E, Valls J, Iniesta R, Moreno V . SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006; 22(15):1928-9. DOI: 10.1093/bioinformatics/btl268. View

19.

Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T . Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol. 2006; 17(8):2127-35. DOI: 10.1681/ASN.2006030205. View

20.

Becker M, Visser L, van Schaik R, Hofman A, Uitterlinden A, Stricker B . Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genomics. 2009; 20(1):38-44. DOI: 10.1097/FPC.0b013e328333bb11. View